In our ETP-ALL cohort, 75% (18/24) of patients with FLT3 mutations showed this immunophenotype, while only 7% (3/44) without FLT3 mutations displayed this phenotype. This evidence concerns the gene FLT3 and acute lymphoblastic leukemia.